Remove FDA Approval Remove Immune Response Remove Life Science Remove Protein
article thumbnail

Talvey Becomes J&J’s Second Multiple Myeloma Bispecific to Score FDA Approval

XTalks

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fifth-line treatment for adult patients with heavily pretreated multiple myeloma.

article thumbnail

2021 Year in Review: Leveraging New Technologies to Drive Innovation in the Life Sciences

XTalks

Xtalks is taking a look at some of the major stories and innovations of the year in the life sciences, many of which were driven by new, emerging and improved technologies. The year 2021 was all about continuing innovations in the life sciences. Life Science Innovations: Malaria and Influenza Vaccines.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Amtagvi (Lifileucel) Scores Landmark Win as First FDA-Approved T-Cell Therapy for a Solid Tumor

XTalks

Iovance Biotherapeutics’ Amtagvi (lifileucel) won US Food and Drug Administration (FDA) approval last week for the treatment of advanced melanoma, making it the first individualized tumor-infiltrating lymphocyte (TIL) therapy and the first T-cell therapy for a solid tumor to win US regulatory approval.

article thumbnail

Amgen’s Tarlatamab Gets FDA Priority Review for Small Cell Lung Cancer

XTalks

Classified as a bispecific T-cell engager (BiTE molecule), tarlatamab consists of two essential parts: one binds to T-cells, vital in immune response, and the other targets cancer cells. Tarlatamab differs from conventional chemotherapy as it’s an immunotherapy designed to help immune cells detect, attach to and fight cancer cells.

article thumbnail

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

New FDA-Approved Treatments For HIV HIV treatment involves the administration of combined antiretroviral therapy (ART) to effectively suppress the viral load, maintain or enhance immune function and reduce the risk of opportunistic infections and cancers commonly associated with HIV. aiming to end the HIV epidemic by 2030.

article thumbnail

Novavax COVID-19 Vaccine Gets Recommended for FDA Emergency Use Authorization

XTalks

The Novavax COVID-19 vaccine was recommended for emergency use in adults by the World Health Organization (WHO) in December 2021 , and is approved in over 40 countries. The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. The Novavax COVID-19 Vaccine Candidate.

article thumbnail

Qalsody (Tofersen) Becomes First-of-Its-Kind Treatment for ALS

XTalks

Qalsody contains tofersen, an antisense oligonucleotide that specifically targets the mRNA made from mutated SODI genes to prevent the formation of toxic SOD1 proteins. Reduction in these two biomarkers in response to tofersen is believed to predict clinical benefit for patients. How Does Qalsody Work?